{"id":"NCT04937387","sponsor":"GlaxoSmithKline","briefTitle":"Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled Asthma","officialTitle":"A Phase III, 12 Week, Randomized, Double-blind, 4 Arm Parallel Group Bridging Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination FF/UMEC/VI Once-daily Via a Dry Powder Inhaler With Dual Combination of FF/VI, Administered in Chinese Participants With Inadequately Controlled Asthma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-07-29","primaryCompletion":"2024-08-05","completion":"2024-08-05","firstPosted":"2021-06-24","resultsPosted":"2025-08-11","lastUpdate":"2025-08-11"},"enrollment":359,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"DRUG","name":"FF/VI","otherNames":[]},{"type":"DRUG","name":"FF/UMEC/VI","otherNames":[]},{"type":"DEVICE","name":"ELLIPTA","otherNames":[]}],"arms":[{"label":"Cohort 1: Participants receiving FF/VI at Dose level 1 via ELLIPTA inhaler","type":"EXPERIMENTAL"},{"label":"Cohort 2: Participants receiving FF/UMEC/VI at Dose level 2 via ELLIPTA inhaler","type":"EXPERIMENTAL"},{"label":"Cohort 3: Participants receiving FF/ VI at Dose level 3 via ELLIPTA inhaler","type":"EXPERIMENTAL"},{"label":"Cohort 4: Participants receiving FF/UMEC/VI at Dose level 4 via ELLIPTA inhaler","type":"EXPERIMENTAL"}],"summary":"The study aims to evaluate the efficacy, safety and tolerability of FF/UMEC/VI compared with FF/VI via ELLIPTAÂ® inhaler in Chinese participants with inadequately controlled asthma. ELLIPTA is a registered trademark of GlaxoSmithKline group of companies.","primaryOutcome":{"measure":"Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12 (100ug FF)","timeFrame":"Baseline (pre-dose at Day 1) and Week 12","effectByArm":[{"arm":"Fluticasone Furoate [FF] 100 Microgram[ug] / Vilanterol [VI] 25 ug","deltaMin":0.078,"sd":0.0321},{"arm":"Fluticasone Furoate [FF] 100 ug/ Umeclidinium [UMEC] 62.5 ug/ Vilanterol [VI] 25 ug","deltaMin":0.136,"sd":0.0316}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":23},"locations":{"siteCount":61,"countries":["China"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":90},"commonTop":["Upper respiratory tract infection","COVID-19","Nasopharyngitis","Rhinitis","Pyrexia"]}}